Lancet Oncol: 10-year follow-up results of high-dose radiotherapy plus long-term androgen deprivation therapy for prostate cancer

The optimal duration of androgen deprivation combined with high-dose radiotherapy for prostate cancer remains controversial

2 years of adjuvant androgen deprivation combined with high-dose radiotherapy significantly improved biochemical control, metastasis, and overall survival in patients, especially in high-risk patients

10

Inclusion criteria for patients in the DART 01/05 trial: 18 years of age or older, histologically diagnosed T1c-T3N0M0 prostate adenocarcinoma, moderate to high risk factors, prostate-specific antigen (PSA) <100 ng/ml, Karnofsky performance score ≥70%

The primary end point at diagnosis was biochemical disease-free survival at 5 years

After a median follow-up of 119.

Only 11 patients died from prostate cancer, all in the high-risk subgroup Only 11 patients died from prostate cancer, all in the high-risk subgroup vascular

Taken together, after 10 years of extended follow-up, the trial's final analysis did not support the significant benefit of LTAD reported at 5-year follow-up

The magnitude of benefit for high-risk patients is clinically meaningful The magnitude of benefit for high-risk patients is clinically meaningful

 

Original source:

Original source:

Almudena Zapatero, et al.

Almudena Zapatero, et al.
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
The Lancet Oncology.
April 12, 2022.
https ://doi.
org/10.
1016/S1470-2045(22)00190-5.


Leave a message here